Verrica Draws Second Complete Response Letter for Manufacturing Deficiencies

By PacConAdmin | May 25, 2022

West Chester, Pa.-based Verrica Pharmaceuticals drew a second Complete Response Letter (CRL) from the FDA rejecting the company’s New Drug Application (NDA) for its investigational drug VP-102 to treat patients with the viral skin disease molluscum contagiosum.
Source: Drug Industry Daily

Posted in Drug Industry Daily